2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.59 (Poster) Minimal Short-Term Mortality in a Diverse, Real-World Lung Cancer Screening Cohort

PP01.59 (Poster) Minimal Short-Term Mortality in a Diverse, Real-World Lung Cancer Screening Cohort

Pdf Summary

A study was conducted to assess short-term mortality in a diverse, real-world lung cancer screening (LCS) cohort. The study aimed to determine whether comorbidity alone should deter clinicians from recommending LCS. The cohort consisted of 1,599 patients undergoing LCS at Parkland Health, a safety-net healthcare provider in Dallas County.<br /><br />The results showed that despite a substantial comorbidity burden, short-term mortality was minimal in this diverse population. With a median follow-up of 17 months, only 33 patients (2%) died. Among those without a date of death, 75% had a healthcare encounter within 3 months of data collection.<br /><br />The study found no significant association between survival and patient characteristics such as sex, race, comorbidity, smoking status, or LCS completion. There was a near-significant association with age, suggesting a slight increase in mortality risk with older age.<br /><br />The study concluded that the findings support the benefits of LCS in diverse populations with comorbidities. Clinicians should not be deterred from recommending LCS based solely on comorbidity, except in cases of end-stage or life-limiting illnesses. The study also emphasized the need for longer follow-up on this and other contemporary LCS cohorts.<br /><br />Overall, the study provides evidence that LCS is beneficial and has minimal short-term mortality in a diverse, real-world setting. These findings have implications for improving lung cancer outcomes in populations with significant tobacco use and comorbidities.

Asset Subtitle

Mary Gwin

Keywords

lung cancer screening

short-term mortality

diverse population

comorbidity burden

healthcare provider

Dallas County

patient characteristics

smoking status

mortality risk

life-limiting illnesses